Eric Kaldjian

Dr. Eric Kaldjian is Chief Medical Officer at RareCyte. He trained in anatomic pathology at the University of Michigan and subsequently at the National Cancer Institute. His pharmaceutical experience at Hoffmann- La Roche and at Parke-Davis/Pfizer encompassed discovery research through full clinical development positions with a focus on translational medicine. He has directed clinical genomics programs at Gene Logic, was Chief Scientific Officer at Transgenomic, and was Medical Director for Companion Diagnostics at Ventana Medical Systems before joining RareCyte, where he oversees scientific and medical applications of its rare cell detection technology. He is an associate member of the BioInterfaces Institute at the University of Michigan.